ORIGINAL RESEARCH—EJACULATORY DISORDERS: Antibiotic Treatment Can Delay Ejaculation in Patients with Premature Ejaculation and Chronic Bacterial Prostatitis

Premature ejaculation (PE) is regarded as the most common male sexual disorder. Previous studies reported that prostatic inflammation was highly prevalent in PE. However, the effect of antibiotic treatment of cases with PE and chronic prostatitis has not been extensively investigated. To examine the effect of antibiotic treatment in delaying ejaculation in patients with PE and chronic prostatitis. The study was carried out in my private chamber and at General Hospital N.Gong from June 2014 to December 2016. The study was performed with prior permission and the confidentiality was maintained. A total of 135 consecutive men attending of secondary premature ejaculation (SPE) were included in this study. Sequential microbiologic specimens were obtained from urine and prostatic fluids. Antibiotics were given for one month according to the results of their culture and sensitivity test. All patients were instructed to follow up in General Hospital N.Gong/Private chamber monthly for at least 4 months. At the end of the 4-month follow-up, another prostatic secretion analysis was performed. Based on expressed prostatic secretion culture and white blood cell (WBC) count, 84 (62.2%) were having chronic bacterial prostatitis. The remaining 51 (37.8%) patients had negative WBC count. Of the 84 patients with secondary premature ejaculation (SPE) and chronic bacterial prostatitis, 20 patients were left untreated and considered as a control group. All 64 patients with PE and chronic prostatitis continued the 1- month treatment duration. Following 1-month antibiotic treatment, all 64 patients with initially positive cultures had sterile final cultures (P < 0.05). Fifty one (79.68%) patients showed increases in their ejaculatory latency time and reported good control of their ejaculation and were considered treatment responsive. None of the control group patients experienced any improvement either in their prostatic infection condition or in their ejaculation time. The follow-up of treatment-responsive patients (N = 51) revealed no recurrence of PE with negative prostatic culture. Successful eradication of causative organisms in patients with PE and chronic prostatitis may lead to marked improvement in intravaginal ejaculatory latency time and ejaculatory control.Medicine Today 2017 Vol.29(2): 21-25

Download Full-text

Long-term Antibiotic Treatment of Chronic Bacterial Prostatitis. Effect on Bacterial Flora

British Journal of Urology ◽

10.1111/j.1464-410x.1989.tb05944.x ◽

1989 ◽

Vol 63 (5) ◽

pp. 503-507 ◽

Cited By ~ 6

Author(s):

B. BERGMAN ◽

H. WEDREN ◽

S. E. Holm

Keyword(s):

Antibiotic Treatment ◽

Bacterial Flora ◽

Chronic Bacterial Prostatitis ◽

Bacterial Prostatitis

Download Full-text

Bacterial Persistence in the Prostate After Antibiotic Treatment of Chronic Bacterial Prostatitis in Men With Spinal Cord Injury

Urology ◽

10.1016/j.urology.2013.11.023 ◽

2014 ◽

Vol 83 (3) ◽

pp. 515-520 ◽

Cited By ~ 8

Author(s):

Jörg Krebs ◽

Peter Bartel ◽

Jürgen Pannek

Keyword(s):

Spinal Cord ◽

Spinal Cord Injury ◽

Antibiotic Treatment ◽

Bacterial Persistence ◽

Chronic Bacterial Prostatitis ◽

Bacterial Prostatitis ◽

Cord Injury

Download Full-text

Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments

Frontiers in Pharmacology ◽

10.3389/fphar.2021.692614 ◽

2021 ◽

Vol 12 ◽

Author(s):

Apurva Virmani Johri ◽

Pranav Johri ◽

Naomi Hoyle ◽

Levan Pipia ◽

Lia Nadareishvili ◽

...

Keyword(s):

Antibiotic Treatment ◽

Pathogenic Bacteria ◽

Phage Therapy ◽

Bacterial Load ◽

Prostate Gland ◽

Resistant Bacteria ◽

Bacteriophage Therapy ◽

Chronic Bacterial Prostatitis ◽

Promising Alternative ◽

Bacterial Prostatitis

Background: Chronic Bacterial Prostatitis (CBP) is an inflammatory condition caused by a persistent bacterial infection of the prostate gland and its surrounding areas in the male pelvic region. It is most common in men under 50 years of age. It is a long-lasting and debilitating condition that severely deteriorates the patient’s quality of life. Anatomical limitations and antimicrobial resistance limit the effectiveness of antibiotic treatment of CBP. Bacteriophage therapy is proposed as a promising alternative treatment of CBP and related infections. Bacteriophage therapy is the use of lytic bacterial viruses to treat bacterial infections. Many cases of CBP are complicated by infections caused by both nosocomial and community acquired multidrug resistant bacteria. Frequently encountered strains include Vancomycin resistant Enterococci, Extended Spectrum Beta Lactam resistant Escherichia coli, other gram-positive organisms such as Staphylococcus and Streptococcus, Enterobacteriaceae such as Klebsiella and Proteus, and Pseudomonas aeruginosa, among others.Case Presentation: We present a patient with the typical manifestations of CBP. The patient underwent multiple courses of antibiotic treatment without any long-term resolution of his symptoms. Testing of prostatic secretion and semen samples revealed pathogenic bacteria in each case, which collectively included members of the Staphylococcal species such as Methicillin resistant Staphylococcus aureus (MRSA) and Staphylococcus haemolyticus, Enterococcus faecalis, and Streptococcus mitis, among others.Methods and Outcome: Bacteriophage preparations from the Eliava Institute were used to treat the patient after establishing phage sensitivity to the pathogenic bacteria. Significant improvements in symptoms and re-testing of samples after bacteriophage treatment indicated a reduction in the bacterial load and resolution of the infection.Discussion: The patient saw significant improvement of symptoms, and positive dynamics in bacterial titers and ultrasound controls after phage therapy. The failure of antibiotic therapy and subsequent success of bacteriophage therapy in treating chronic bacterial prostatitis shows the effectiveness of bacteriophages in controlling chronic infections in areas of low vascularity and anatomical complexity. These cases also highlight the efficacy of phages in overcoming antibiotic-resistant infections as well as biofilm infections.

Download Full-text

99: Prulifloxacin Versus Levofloxacin in the Treatment of Chronic Bacterial Prostatitis: A Prospective, Randomized, Double-Blind Trial

The Journal of Urology ◽

10.1016/s0022-5347(18)30364-1 ◽

2007 ◽

Vol 177 (4S) ◽

pp. 35-35

Author(s):

Gianluca Giannarini ◽

Andrea Mogorovich ◽

Girolamo Morelli ◽

Maurizio De Maria ◽

Francesca Manassero ◽

...

Keyword(s):

Double Blind Trial ◽

Chronic Bacterial Prostatitis ◽

Double Blind ◽

Blind Trial ◽

Bacterial Prostatitis

Download Full-text

Faculty Opinions recommendation of Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725367901.793536460 ◽

2017 ◽

Author(s):

Jaspreet Sandhu

Keyword(s):

Pelvic Pain ◽

Chronic Prostatitis ◽

Chronic Pelvic Pain ◽

Chronic Pelvic Pain Syndrome ◽

Pain Syndrome ◽

Diagnosis And Treatment ◽

Pelvic Pain Syndrome ◽

Consensus Guideline ◽

Chronic Bacterial Prostatitis ◽

Bacterial Prostatitis

Download Full-text

The use of Lactobacillus casei DG® prevents symptomatic episodes and reduces the antibiotic use in patients affected by chronic bacterial prostatitis: results from a phase IV study

World Journal of Urology ◽

10.1007/s00345-020-03580-7 ◽

2021 ◽

Author(s):

Tommaso Cai ◽

Luca Gallelli ◽

Erika Cione ◽

Gianpaolo Perletti ◽

Francesco Ciarleglio ◽

...

Keyword(s):

Quality Of Life ◽

Clinical Symptoms ◽

Clinical Status ◽

Well Being ◽

Antibiotic Use ◽

Chronic Bacterial Prostatitis ◽

Symptomatic Recurrence ◽

Bacterial Prostatitis ◽

Phase Iv

Abstract Purpose To evaluate the efficacy of Lactobacillus paracasei CNCM I-1572 (L. casei DG®) in both prevention of symptomatic recurrences and improvement of quality of life in patients with chronic bacterial prostatitis (CBP). Methods Patients with CBP attending a single Urological Institution were enrolled in this phase IV study. At enrollment, all patients were treated with antibiotics in agreement with EAU guidelines and then were treated with L. casei DG® (2 capsules/day for 3 months). Clinical and microbiological analyses were carried out before (enrollment, T0) and 6 months (T2) after the treatment. Both safety and adherence to the treatment were evaluated 3 months (T1) after the enrollment. NIH Chronic Prostatitis Symptom Index (CPSI), International Prostate Symptom Score (IPSS) and Quality of Well-Being (QoL) questionnaires were used. The outcome measures were the rate of symptomatic recurrence, changes in questionnaire symptom scores and the reduction of antibiotic use. Results Eighty-four patients were included. At T2, 61 patients (72.6%) reported a clinical improvement of symptoms with a return to their clinical status before symptoms. A time dependent improvement in clinical symptoms with significant changes in NIH-CPSI, IPSS and QoL (mean difference T2 vs T0: 16.5 ± 3.58; − 11.0 ± 4.32; + 0.3 ± 0.09; p < 0.001), was reported. We recorded that L. casei DG® treatment induced a statistically significant decrease in both (p < 0.001) symptomatic recurrence [1.9/3 months vs 0.5/3 months] and antibiotic use [− 7938 UDD]. No clinically relevant adverse effects were reported. Conclusions L. casei DG® prevents symptomatic recurrences and improves the quality of life in patients with CBP, reducing the antibiotic use.

Download Full-text